Fosaprepitant is a prodrug of aprepitant for injection.
Aprepitant treatment is given along with a 5-HT3-receptor antagonist and dexamethasone.
- TRADE NAME: Emend (Merck)
- INDICATIONS: Prevention of postoperative and chemotherapy induced nausea and vomiting
- CLASS: Antiemetic, CYP3A4 inhibitor, Neurokinin 1 receptor antagonist
- HALF-LIFE: 9–13 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Alprazolam, Antifungal agents, Astemizole, Avanafil, Betamethasone, Carbamazepine, Cisapride, Clarithromycin, Colchicine, Conivaptan, Corticosteroids, CYP2C9 substrates, CYP3A4 inducers or inhibitors, Dasatinib, Deferasirox, Dexamethasone, Diltiazem, Docetaxel, Eplerenone, Estrogens, Everolimus, Fentanyl, Grapefruit Juice, Halofantrine, Ifosfamide, Imatinib, Irinotecan, Itraconazole, Ketoconazole, Lumateperone, Methylprednisolone, Midazolam, Mifepristone, Naldemedine, Nefazodone, Neratinib, Olaparib, Oral Contraceptives, Paroxetine Hydrochloride, Phenobarbital, Phenytoin, Pimecrolimus, Pimozide, Progestins, Ranolazine, Rifampin, Rifamycin derivatives, Rifapentine, Ritonavir, Salmeterol, Saxagliptin, St John's Wort, Telithromycin, Terfenadine, Tolbutamide, Tolvaptan, Trabectedin, Triamcinolone, Troleandomycin, Vinblastine, Vincristine, Voriconazole, Warfarin - PREGNANCY: Insufficient evidence to inform drug-associated risk
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of aprepitant in the Informa Healthcare journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 07/31/2023
